Advances in the pharmacotherapy of Heart Failure: type 2 sodium-glucose cotransporter Inhibitors (SGLT2) as a therapeutic option

Authors

DOI:

https://doi.org/10.33448/rsd-v12i3.40502

Keywords:

Sodium-Glucose Transporter 2 Inhibitors; Heart Failure; Efficacy.

Abstract

Despite the therapeutic options currently available for Heart Failure (HF), this pathology is still responsible for high rates of morbidity and mortality in the population. Faced with these current therapeutic limitations, the development of studies to evaluate the effectiveness of new drugs in HF is justified, among them the sodium-glucose cotransporter type 2 (SGLT2) inhibitors. In this context, the objective of this work is to evaluate the benefits and limitations of SGLT2 inhibitors in the management of HF. The present study is an integrative literature review carried out from the PubMed and VHL databases. Seven randomized clinical studies controlled by placebo were analyzed, from which it was verified that SGLT2 inhibitors presented promising therapeutic effect, with cardioprotective and renoprotective action, in a broad spectrum of HF, reducing the risk of hospitalizations and deaths from causes cardiovascular effects, regardless of the presence or absence of DM2, in addition to being safe and well tolerated. Therefore, the use of SGLT2 inhibitors represents an additional effective and safe therapeutic alternative with the potential to modify the morbidity and mortality of HF.

References

Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M. & Packer, M. (2021). Empagliflozin in Heart Failure with a Preserved Ejection Fraction. The new England journal of medicine, 385(16), 1451-61. 10.1056/NEJMoa2107038

Böhm, M., Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Pocock, S. J. & Packer, M. (2021). Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. Journal of the American College of Cardiology, 78(13), 1337–48. https://doi.org/10.1016/j.jacc.2021.07.049

Braga, F. G. M., Ramires, F. J. A., Figueiredo, E. L., Neto, J. A. F., Silva, L. B., & Rassi, S. (2020). Tópicos Emergentes em Insuficiência Cardíaca: Nova Era do Tratamento Farmacológico. Arq Bras Cardiol, 115(5), 956-60. https://doi.org/10.36660/abc.20201106

Cardoso, J. S., Andrade, A., Brito, D., Ferreira, J., Fonseca, C., Peres, M., Francok, F., & Moura, B. (2021). SGLT-2 inhibitors: a step forward in the treatment of heart failure with reduced ejection fraction. Revista Portuguesa de Cardiologia (English Edition), 40(9), 687-693. http://dx.doi.org/10.1016/j.repce.2021.02.006

Docherty, K. F., Jhund, P. S., Claggett, B., Ferreira, J. P., Bengtsson, O., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez F. A., Ponikowski. P., Sabatine, M. S., Sjöstrand, M., Solomon. S. D., & McMurray. J. J. V. (2021). Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction. JAMA Cardiology, 6(11), 1298-1305. 10.1001/jamacardio.2021.2632

Galvão, M. C. B., & Ricarte, I. L. M. (2020). Revisão sistemática da literatura: conceituação, produção e publicação. Logeion: Filosofia da informação, 6(1), 57-73. https://doi.org/10.21728/logeion.2019v6n1.p57-73

Lan, N. S. R., Fegan, P. G., Yeap, B. B., & Dwivedi, G. (2019). The effects of sodium‐glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions. ESC heart failure, 6(5), 927-935. https://DOI: 10.1002/ehf2.12505

Lara, R. A. M., Bessa, L. L. C., Silveira, A. V. D., Souza, I. G., Ferreira, G. F. S., Souza, G. P., & França, D. S. (2021). Análise epidemiológica da insuficiência cardíaca no brasil. Brazilian Medical Students Journal, 6(9), 1-8. 10.53843/bms.v6i9.224

Latorraca, C.O. C., Rodrigues, M., Pacheco, R. L., Martimbianco, A. L. C., & Riera, R. (2019). Busca em bases de dados eletrônicas da área da saúde: por onde começar. Revista Diagnóstico e Tratamento, 24(2), 59-63. https://docs.bvsalud.org/biblioref/2019/09/1015338/rdt_v24n2_59-63.pdf

Li, H. L., Lip, G. Y. H., Feng, Q., Fei, Y., Tse, Y. K., Wu, M., Ren, Q. W., Tse, H. F., Cheung, B. M. Y., & Yiu, K. H. (2021). Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis. Cardiovascular Diabetology, 20(1), 1-13. Springer Science and Business Media LLC. http://dx.doi.org/10.1186/s12933-021-01293-8

Martins, C. N. G., Bau, A. A., Silva, L. M., & Filho, O. R. C. (2021). Possíveis Mecanismos dos Inibidores de SGLT2 na Insuficiência Cardíaca. ABC Heart Fail Cardiomyop, 1(1), 33-43. https://doi.org/10.36660/abchf.20210007

McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., Böhm, M., Chiang, C. E., Chopra, V. K., Boer, R. A., Desai, A. S., Diez, M., Drozdz, J., Dukát, A., Ge, J., Howlett, J. G., Katova, T., Kitakaze, M., Ljungman, C. E. A., Merkely, B., Nicolau, J. C., Meara, E. O., Petrie M. C., Vinh, P. N., Schou, M., Tereshchenko, S., Verma, S., Held, C., DeMets, D. L., Docherty, K. F., Jhund, P. S., Bengtsson, O., Sjöstrand, M., & Langkilde, A. M. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. The new England journal of medicine, 381(21), 1995-2008. 10.1056/NEJMoa1911303

Nassif, M. E., Windsor, S. L., Borlaug, B. A., Kitzman, D. W., Shah, S. J., Tang, F., Khariton, Y., Malik, A. O., Khumri, T., Umpierrez, G., Lamba, S., Sharma, K., Khan, S. S., Chandra, L., Gordon, R. A., Ryan, J. J., Chaudhry, S. P., Joseph, S. M., Chow, C. H., Kanwar, M. K., Pursley, M., Siraj, E. S., Lewis, G. D., Clemson, B. S., Fong, M., & Kosiborod, M. N. (2021). The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nature Medicine, 27(11), 1954–1960. https://doi.org/10.1038/s41591-021-01536-x

Sharma, N., Srivastav, A. K., & Samuel, A. J. (2020). Ensaio clínico randomizado: padrão ouro de desenhos experimentais - importância, vantagens, desvantagens e preconceitos. Rev Pesqui Fisioter, 10(3), 512-519. https://doi: 10.17267/2238-2704rpf.v10i3.3039

Sociedade Brasileira de Cardiologia (2018). Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda. Arq Bras Cardiol, 111(3), 436-539. 10.5935/abc.20180190

Spertus, J. A., Birmingham, M. C., Nassif, M., Damaraju, C. V., Abbate, A., Butler, J., Lanfear, D. E., Lingvay, I., Kosiborod, M. N., & Januzzi, J. L. (2022). The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nature Medicine, 28(4), 809–813. https://doi.org/10.1038/s41591-022-01703-8

Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., Jamal, W., Kimura, K., Schnee, J., Zeller, C., Cotton, D., Bocchi, E., Böhm, M., Choi, D. J., Chopra, V., Chuquiure, E., Giannetti, N., Janssens, S,. Zhang, J., Juanatey, J. R. G., Kaul, S., Rocca, H. P. B. L., Merkely, B., Nicholls, S. J., Perrone, S., Pina, I., Ponikowski, P., Sattar, N., Senni, M., Seronde, M. F., Spinar, J., Squire, I., Taddei, S., Wanner, C., & Zannad, F. (2020). Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. The new England journal of medicine, 383(15), 1413-1424. 10.1056/NEJMoa2022190

Pereira, G. A. R., & Silva, L. B. (2022). Iron Deficiency in Heart Failure with Reduced Ejection Fraction: Pathophysiology, Diagnosis and Treatment. Arquivos brasileiros de cardiologia, 118(3), 646-654. https://doi:10.36660/abc.20201257

Pradhan, A., Vohra, S., Vishwakarma, P., & Sethi, R. (2019). Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure. J Family Med Prim Care, 8(6), 1855-1862. 10.4103/jfmpc.jfmpc_232_19

Voors, A. A., Angermann, C. E., Teerlink, J. R., Collins, S. P., Kosiborod, M., Biegus, J. & Ponikowski, P. (2022). The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nature medicine, 28(3), 568–574. https://doi.org/10.1038/s41591-021-01659-1

Published

01/03/2023

How to Cite

SOARES, M. M. B. .; LUZ, A. M. C. .; SILVA, J. N. B. .; GUIMARÃES, L. F. da S. .; SOUSA, D. M. de; SILVA, E. L. da C. .; MARTINS, I. R. R. . Advances in the pharmacotherapy of Heart Failure: type 2 sodium-glucose cotransporter Inhibitors (SGLT2) as a therapeutic option. Research, Society and Development, [S. l.], v. 12, n. 3, p. e12412340502, 2023. DOI: 10.33448/rsd-v12i3.40502. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/40502. Acesso em: 5 oct. 2024.

Issue

Section

Health Sciences